BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37629066)

  • 1. Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma.
    Maász A; Bodó T; Till Á; Molnár G; Masszi G; Labossa G; Herbert Z; Bene J; Hadzsiev K
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report.
    Cavalheiro S; da Costa MDS; Richtmann R
    Childs Nerv Syst; 2021 Dec; 37(12):3897-3899. PubMed ID: 34008055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
    Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.
    Goyer I; Dahdah N; Major P
    Pediatr Neurol; 2015 Apr; 52(4):450-3. PubMed ID: 25682485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study.
    Ebrahimi-Fakhari D; Mann LL; Poryo M; Graf N; von Kries R; Heinrich B; Ebrahimi-Fakhari D; Flotats-Bastardas M; Gortner L; Zemlin M; Meyer S
    Orphanet J Rare Dis; 2018 Jul; 13(1):117. PubMed ID: 30016967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenatal diagnosis of giant cardiac rhabdomyoma in tuberous sclerosis complex: a new therapeutic option with everolimus.
    Mlczoch E; Hanslik A; Luckner D; Kitzmüller E; Prayer D; Michel-Behnke I
    Ultrasound Obstet Gynecol; 2015 May; 45(5):618-21. PubMed ID: 24913039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of a cardiac rhabdomyoma in a patient receiving everolimus.
    Tiberio D; Franz DN; Phillips JR
    Pediatrics; 2011 May; 127(5):e1335-7. PubMed ID: 21464184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
    Doğan V; Yeşil Ş; Kayalı Ş; Beken S; Özgür S; Ertuğrul İ; Bozkurt C; Örün UA; Karademir S
    J Trop Pediatr; 2015 Feb; 61(1):74-7. PubMed ID: 25344617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
    Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
    Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
    Lechuga L; Franz DN
    Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
    [No Abstract]   [Full Text] [Related]  

  • 13. Everolimus for severe arrhythmias in tuberous sclerosis complex related cardiac rhabdomyomas.
    Silva-Sánchez MP; Alvarado-Socarras JL; Castro-Monsalve J; Meneses KM; Santiago J; Prada CE
    Am J Med Genet A; 2021 May; 185(5):1525-1531. PubMed ID: 33590972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
    Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
    Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fetal cardiac tumor: echocardiography, clinical outcome and genetic analysis in 53 cases.
    Chen J; Wang J; Sun H; Gu X; Hao X; Fu Y; Zhang Y; Liu X; Zhang H; Han L; He Y
    Ultrasound Obstet Gynecol; 2019 Jul; 54(1):103-109. PubMed ID: 29877000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
    Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients' Perspectives.
    Willems LM; Rosenow F; Schubert-Bast S; Kurlemann G; Zöllner JP; Bast T; Bertsche A; Bettendorf U; Ebrahimi-Fakhari D; Grau J; Hahn A; Hartmann H; Hertzberg C; Hornemann F; Immisch I; Jacobs J; Klein KM; Klotz KA; Kluger G; Knake S; Knuf M; Marquard K; Mayer T; Meyer S; Muhle H; Müller-Schlüter K; von Podewils F; Ruf S; Sauter M; Schäfer H; Schlump JU; Syrbe S; Thiels C; Trollmann R; Wiemer-Kruel A; Wilken B; Zukunft B; Strzelczyk A
    CNS Drugs; 2021 Oct; 35(10):1107-1122. PubMed ID: 34275102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. The ORACLE study protocol (everOlimus for caRdiac rhAbdomyomas in tuberous sCLErosis): a randomised, multicentre, placebo-controlled, double-blind phase II trial.
    Stelmaszewski EV; Parente DB; Farina A; Stein A; Gutierrez A; Raquelo-Menegassio AF; Manterola C; de Sousa CF; Victor C; Maki D; Morón EM; de Abrantes FF; Iqbal F; Camacho-Vilchez J; Jimenez-Pavón J; Polania JP; Thompson L; Bonanato L; Diebold M; Da Silva MVCP; Nashwan MWJ; Galvani MAG; Idris OEA; Danos P; Ortiz-Lopez R; Mahmoud RAA; Gresse S; Loss KL
    Cardiol Young; 2020 Mar; 30(3):337-345. PubMed ID: 31983379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term use of everolimus for refractory arrhythmia in a child with tuberous sclerosis complex.
    Hofmann C; Syrbe S; Hebe J; Kreft J; Stark S; Milde T; Völkers M; Hoffmann GF; Gorenflo M; Kovacevic A
    Am J Med Genet A; 2024 May; 194(5):e63508. PubMed ID: 38130096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal cardiac rhabdomyoma due to paternal mosaicism of TSC2: A case report.
    Chen L; Jiang Y; Wang J
    Medicine (Baltimore); 2020 Aug; 99(35):e21949. PubMed ID: 32871942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.